Miederer Matthias, Benešová-Schäfer Martina, Mamat Constantin, Kästner David, Pretze Marc, Michler Enrico, Brogsitter Claudia, Kotzerke Jörg, Kopka Klaus, Scheinberg David A, McDevitt Michael R
Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany.
Medizinische Fakultät and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Pharmaceuticals (Basel). 2024 Jan 8;17(1):76. doi: 10.3390/ph17010076.
The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.
使用放射性核素进行靶向内照射治疗是肿瘤学中一个快速发展的领域。特别是,关注不同辐射质量的生物学效应是理解和实施新疗法的一个重要因素。随着成像与治疗相结合的方法,治疗性核医学最近取得了很大进展。一个特定的研究领域是使用发射α粒子的放射性核素,其具有与突出优势相关的独特物理特性,例如用于单个肿瘤细胞靶向。本文讨论了关于发射α粒子同位素的生产、它们与载体分子的化学结合以及来自同情用药报告和临床试验的临床经验的最新结果和未解决的问题。